Drug Profile
Research programme: gold nanoparticle based therapy - Oraya Therapeutics
Alternative Names: Gold nanoparticles - Oraya TherapeuticsLatest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator Oraya Therapeutics
- Developer Dana-Farber Cancer Institute; Oraya Therapeutics
- Class Heavy metals
- Mechanism of Action Angiogenesis inhibitors; Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Wet age-related macular degeneration
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for research development in Wet age-related macular degeneration in USA (IV)
- 05 Aug 2014 Oraya Therapeutics receives Small Business Technology Transfer grant from NIH for the development of gold nanoparticles in Wet age-related macular degeneration
- 05 Aug 2014 Early research in Wet age-related macular degeneration in USA (IV)